Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783766 | 0.83 | PRNP (0.39) | AXLLMNANPSR1KMT2ARAB9A | |
| SCHEMBL26054505 | 0.78 | LMNA (0.40) | AXLLMNANPSR1KMT2ARAB9A | |
| SCHEMBL16866359 | 0.78 | KMT2A (0.53) | LMNANPSR1KMT2AMEN1NPC1 | |
| SCHEMBL16429551 | 0.74 | ALDH1A1 (0.48) | NPSR1KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL8297325 | 0.74 | HPGD (0.39) | LMNANPSR1KMT2ARAB9AMEN1 | |
| SCHEMBL159280 | 0.73 | — | — | |
| SCHEMBL10862218 | 0.71 | GSK3B (0.57) | AXLLMNAPTPN2PTPN1ABCC1 | |
| Hydrochloric Acid SCHEMBL3044528 | 0.71 | GSK3B (0.57) | AXLLMNAPTPN2PTPN1ABCC1 | |
| SCHEMBL69159 | 0.70 | ALDH1A1 (0.58) | AXLLMNAPTPN2PTPN1ABCC1 | |
| SCHEMBL1162100 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8927569-B2 | Macrocyclic compounds as antiviral agents | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| EP-2178902-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-11-28 | — | — | EP | disclosed |
| CN-102753552-A | Novel pyrrolopyridine benzoate derivatives | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| CN-102596906-A | Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease | FOURNIER LAB SA | 2012-07-18 | — | — | CN | disclosed |
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2178902-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010804-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | AXL 378/4885LMNA 4871/4885PTPN2 20/4885 |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | AXL 378/4885LMNA 4871/4885PTPN2 20/4885 |
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, RNASE1, RRP1B | AXL 3705/4885LMNA 1699/4885PTPN2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.